Business
    Next Score View the next score

    Mass. Movers

    Merck acquires Idenix, hepatitis C drug maker

    Merck agreed to pay $3.85 billion for Idenix.
    Associated Press
    Merck agreed to pay $3.85 billion for Idenix.

    Shares of Cambridge-based Idenix Pharmaceuticals Inc. soared this week after Merck & Co. agreed to pay $3.85 billion for the biotech that is developing drugs to cure hepatitis C, a staggering price for a small company with fewer than 100 employees. The market for hepatitis C treatments, estimated at $200 billion worldwide over the next decade and an half, is dominated by Sovaldi, a fast-selling pill made by California’s Gilead Sciences Inc.

    Advertisement